Cellares has raised $617.0M in total across 4 funding rounds.
Cellares's investors include BlackRock, Eclipse Ventures, Baillie Gifford, Decheng Capital, DFJ Growth, Duquesne Family Office, EDBI, Gates Frontier Fund, Intuitive Ventures, T. Rowe Price, Willett Advisors LLC, General Catalyst.
Cellares is a biotechnology company pioneering automated, scalable manufacturing for cell therapies as the first Integrated Development and Manufacturing Organization (IDMO).[1][3][5] It builds the Cell Shuttle, a "factory in a box" platform that automates end-to-end production of suspension-based cell therapies, alongside the Cell Q quality control system, enabling Smart Factories to produce up to 10x more therapies at 50% lower batch costs while serving biotech and pharma developers from preclinical to commercial stages.[1][2][4][5] This solves key bottlenecks in conventional CDMOs—scalability, high costs, labor intensity, and process failures—by offering immediate economies of scale for early-stage therapies and global capacity for approved ones, with facilities in South San Francisco, Bridgewater (NJ), and expansions in Europe and Japan.[1][5] Backed by over $355 million in funding, Cellares shows explosive growth, posting a 5,592% two-year revenue increase to become the Bay Area's fastest-growing private company.[1][6]
Cellares was founded in April 2019 in South San Francisco, California, by Fabian Gerlinghaus (CEO), who identified cell therapy manufacturing gaps during market research and industry conferences in a prior role.[2][3] Gerlinghaus spotted the urgent need for fully automated, closed, and scalable systems to produce life-saving therapies at industrial volumes, as developers repeatedly highlighted limitations of traditional methods.[2] Early traction came from developing the Cell Shuttle, an FDA-designated Advanced Manufacturing Technology that expedites regulatory reviews, fueling rapid scaling with $355+ million raised from top investors and the launch of its first commercial Smart Factory in Bridgewater, NJ.[1][2]
Cellares stands out through its Industry 4.0 automation stack, outperforming conventional CDMOs in key metrics:
Cellares rides the cell and gene therapy boom, where demand for personalized "living drugs" outstrips outdated manufacturing—conventional CDMOs struggle with variability, high costs, and limited scale amid a market projected to explode as therapies like CAR-T gain approvals.[1][2][5] Timing is ideal post-2017 FDA nods for first cell therapies, amplifying needs for automation as patient pipelines grow; Cellares' platform mitigates risks like process failures (75% reduction) and enables mass production to reach "total global patient demand."[1][2] It influences the ecosystem by partnering with developers for small-volume scaling and commercial capacity, fostering biotech innovation while competitors like Multiply Labs or Cellino focus on narrower robotics or AI bioprocessing.[3]
Cellares is primed for dominance in cell therapy manufacturing, with Europe/Japan factories online soon to cement its global IDMO leadership and revenue trajectory building on its 5,592% growth spurt.[1][5][6] Trends like AI-driven bioprocessing, regulatory fast-tracks, and surging therapy approvals will propel adoption, potentially slashing costs further and unlocking underserved patients. Its influence could evolve from enabler to standard-setter, transforming biotech from artisanal to industrial scale and accelerating life-saving therapies worldwide—echoing its founding mission to mass-manufacture the "living drugs of the 21st century."[1][2]
Cellares has raised $617.0M across 4 funding rounds. Most recently, it raised $257.0M Series D in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 28, 2026 | $257.0M Series D | BlackRock, Eclipse Ventures | Baillie Gifford, Decheng Capital, DFJ Growth, Duquesne Family Office, EDBI, Gates Frontier Fund, Intuitive Ventures, T. Rowe Price, Willett Advisors LLC |
| Aug 1, 2023 | $260.0M Series C | Eclipse Ventures, General Catalyst, Long Journey Ventures, Renegade Partners | |
| May 1, 2021 | $82.0M Series B | Eclipse Ventures, General Catalyst, Long Journey Ventures, Renegade Partners | |
| Oct 1, 2020 | $18.0M Series A | Eclipse Ventures, General Catalyst, Long Journey Ventures, Renegade Partners |
